CTNM

8.6803.98%
SB

Sarah Boyce

Independent Director

Ms. Sarah Boyce is Director of Abcuro, Inc. from July 2024. She is Independent Director of Contineum Therapeutics, Inc. from June 2024. She is Independent Chair of the Board of Director of Atrium Therapeutics, Inc. from December 2025. She is Advisor of RA Capital Management, L.P. from 2026. She was Independent Director of Ligand Pharmaceuticals Incorporated from October 15, 2019 to November 2022. She was employed at Ligand Pharmaceuticals Incorporated from October 15, 2019 to November 2022. She was Chief Business Officer of Ionis Pharmaceuticals, Inc. from January 2015 to April 16, 2018. She was employed at Ionis Pharmaceuticals, Inc. from January 2015 to April 16, 2018. She was President, CEO & Director of Avidity Biosciences, Inc. from October 2019 to February 27, 2026. She was employed at Avidity Biosciences, Inc. from October 2019 to February 27, 2026. She was Independent Director of Bruker Cellular Analysis, Inc. from August 2019 to May 26, 2022. She was employed at Bruker Cellular Analysis, Inc. until May 26, 2022. She was President & Director of Akcea Therapeutics, Inc. from April 17, 2018 to September 18, 2019. She was employed at Akcea Therapeutics, Inc. from April 17, 2018 to September 18, 2019. She was Independent Director of OmniAb, Inc. from November 01, 2022 to April 18, 2025. She was employed at OmniAb, Inc. from November 01, 2022 to April 18, 2025. She has B.S. in Microbiology from University of Manchester in 1993.

Positions